Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys

Toxicology and Applied Pharmacology

Volumn 158, Issue 2, 1999, Pages 152-160

  Hotchkiss, Charlotte E ^a   Hall, Philip D ^b   Cline, J Mark ^a   Willingham, Mark C ^a   Kreitman, Robert J ^d   Gardin, Jean ^a   Latimer, Amy ^a   Ramage, Jason ^a   Feely, Theodore ^a   DeLatte, Stephen ^c   Tagge, Edward P ^c   Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Diphtheria toxin; Fusion toxin; GM CSF

Indexed keywords

ANTINEOPLASTIC AGENT; DIPHTHERIA TOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FEMALE; HYPOALBUMINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; NEUTROPENIA; NONHUMAN; SEPSIS; STEM CELL; THROMBOCYTOPENIA; TOXICITY TESTING;

ANIMALIA; MACACA FASCICULARIS;

EID: 0033566104     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8691     Document Type: Article

References (30)

1. Amlot P., Stone M., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P., Uhr J., Vitetta E. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 82:1993;2624-2633.
2. Bennett J. M., Young M. L., Andersen J. W., Cassileth P. A., Tallman M. S., Paietta E., Wiernik P. H., Rowe J. M. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer. 80:1997;2205-2209.
3. Cannistra S. A., Groshek P., Garlick R., Miller J., Griffin J. D. Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor in normal human myeloid cells. Proc. Natl. Acad. Sci. USA. 87:1990;93-97.
4. Chan C. H., Blazar B. R., Eide C. R., Kreitman R. J., Vallera D. A. A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells. Blood. 86:1995;2732-2740.
5. Choe S., Bennett M. T., Fuji G., Curmi P. M. G., Kantardjieff K. A., Collier R. J., Eisenberg D. The crystal structure of diphtheria toxin. Nature. 357:1992;216-222.
6. Cohen D., Green M. S., Katzenelson E., Slepon R., Bercovier H., Wiener M. Long-term persistence of anti-diphtheria toxin antibodies among adults in Israel. Implications for vaccine policy. Eur. J. Epidemiol. 10:1994;267-270.
7. Frankel A. E., FitzGerald D., Siegall C., Press O. W. Advances in immunotoxin biology and therapy: A summary of the fourth international symposium on immunotoxins. Cancer Res. 56:1996;926-932.
8. Frankel A. E., Hall P. D., Burbage C., Vesely J., Willingham M. C., Bhalla K., Kreitman R. J. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 90:1997a;3654-3661.
9. Frankel A. E., Laver J. H., Willingham M. C., Burns L. J., Kersey J. H., Vallera D. A. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk. Lymphoma. 26:1997b;287-298.
10. Frankel A. E., Lilly M., Kreitman R. J., Hogge D., Beran M., Freedman M. H., Emanuel P. D., McLain C., Hall P. D., Tagge E. P., Berger M., Eaves C. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 92:1998a;4279-4286.
11. Frankel A. E., Hall P. D., McLain C., Safa A. R., Tagge E. P., Kreitman R. J. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconj. Chem. 9:1998b;490-496.
12. Gould B., Borowitz M., Groves E., Carter P., Anthony D., Weiner L., Frankel A. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies. J. Natl. Cancer Inst. 81:1989;775-781.
13. Hall P. D., Kreitman R. J., Willingham M. C., Frankel A. E. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicol. Appl. Pharmacol. 150:1998;91-97.
14. Hall P. D., Willingham M. C., Kreitman R. J., Frankel A. E. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999.
15. Hertler A., Schlossman D., Borowitz M., Blythman H., Casellas P., Frankel A. An anti-CD5-immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin-monensin. Int. J. Cancer. 43:1989;215-219.
16. Hogge D. E., Wilman C. L., Kreitman R. J., Berger M., Hall P. D., Kopecky K. J., McLain C., Tagge E. P., Eaves C. J., Frankel A. E. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 92:1998;589-595.
17. Kim, C. N., Bhalla, K., Kreitman, R. J., Willingham, M. C., Hall, P. D., Tagge, E. P., Jia, T., and Frankel, A. E.1999. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and ara-C exert synergistic toxicity against human AML HL-60 cells [Submitted for publication].
18. Kreitman R. J., Pastan I. Recombinant ptoxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood. 90:1997;252-259.
19. List A. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 10:1996;S4-S6.
20. Maloney D. G., Grillo-Lopez A. J., White C. A., Bodkiin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Roysteon I., Davis T., Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
21. Mayer R. J., Davis R. B., Schiffer C. A., Berg D. T., Powell B. L., Schulman P., Omura G. A., Moore J. O., McIntyre O. R., Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl. J. Med. 331:1994;896-903.
22. Myers L. A., Boyce J. T., Robison R. L. The tolerability and pharmacology of interleukin-6 administered in combination with GM-CSF or G-CSF in the rhesus monkey. Toxicology. 101:1995;157-166.
23. Parentesis J. P., Gunther R., Waurzyniak B., Yanishevski Y., Myers D. E., Ek O., Messinger Y., Shao Y., Chelstrom L. M., Schneider E., Evans W. E., Uckun F. M. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte-macrophage colony-stimulating factor receptor. Clin. Cancer Res. 3:1997;2217-2227.
24. Parker S., Tong T., Bolden S., Wingo P. Cancer statistics. (1997). CA Cancer J. Clin. 47:1997;5-27.
25. Pisciotta A. V., Santos A. S., Keller C. Studies on agranulocytosis. V. Patterns of recovery from drug-induced bone marrow damage. J. Lab. Clin. Med. 63:1964;445-455.
26. Uckun F. M., Yanishevski Y., Tumer N., Waurzyniak B., Messinger Y., Chelstrom L. M., Lisowski E. A., Ek O., Zeren T., Wendorf H., Langlie M. C., Irvin J. D., Myers D. E., Fuller G. B., Evans W., Gunther R. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Clin. Cancer Res. 3:1997;325-337.
27. Uhr M. R., Schaufelberger H. D., Hildebrand P., Beglinger C. Thrombocytes express functional cytokine receptors in patients with Crohn disease and ulcerative colitis. Schweiz. Med. Wochenschr. 125:1995;970-974.
28. Wognum A. W., Westerman Y., Visser T. P., Wagemaker G. Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood. 84:1994;764-774.
29. Wortham C., Grinberg L., Kaslow D. C., Briles D. E., McDaniel L. S., Lees A., Flora M., Snapper C. M., Mond J. J. Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infect. Immun. 66:1998;1513-1520.
30. Yamaizumi M., Mekada E., Uchida T., Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 15:1978;245-250.